Role of lipopolysaccharide sialylation in serum resistance of serogroup B and C meningococcal disease isolates.
about
The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complementLarge-scale analysis of the meningococcus genome by gene disruption: resistance to complement-mediated lysis.Insights into the evolution of sialic acid catabolism among bacteria.Inhibition of the alternative pathway of nonhuman infant complement by porin B2 contributes to virulence of Neisseria meningitidis in the infant rat modelUpdate on meningococcal disease with emphasis on pathogenesis and clinical managementInhibition of the classical pathway of complement by meningococcal capsular polysaccharidesAbrogation of neuraminidase reduces biofilm formation, capsule biosynthesis, and virulence of Porphyromonas gingivalis.An evaluation of the role of properdin in alternative pathway activation on Neisseria meningitidis and Neisseria gonorrhoeae.Enhanced factor H binding to sialylated Gonococci is restricted to the sialylated lacto-N-neotetraose lipooligosaccharide species: implications for serum resistance and evidence for a bifunctional lipooligosaccharide sialyltransferase in GonococciThe Neisseria lipooligosaccharide-specific alpha-2,3-sialyltransferase is a surface-exposed outer membrane protein.Meningococcal disease and the complement system.Differential expression and transcriptional analysis of the alpha-2,3-sialyltransferase gene in pathogenic Neisseria sppMeningococcal group W-135 and Y capsular polysaccharides paradoxically enhance activation of the alternative pathway of complement.α-2,3-sialyltransferase expression level impacts the kinetics of lipooligosaccharide sialylation, complement resistance, and the ability of Neisseria gonorrhoeae to colonize the murine genital tractEnhanced bacteremia in human factor H transgenic rats infected by Neisseria meningitidisBacteremia in an immunocompromised patient caused by a commensal Neisseria meningitidis strain harboring the capsule null locus (cnl).Available carbon source influences the resistance of Neisseria meningitidis against complement.Defining targets for complement components C4b and C3b on the pathogenic neisseriaeThe meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistanceEffect of host lactate on gonococci and meningococci: new concepts on the role of metabolites in pathogenicity.Functional comparison of the binding of factor H short consensus repeat 6 (SCR 6) to factor H binding protein from Neisseria meningitidis and the binding of factor H SCR 18 to 20 to Neisseria gonorrhoeae porin.Sialic acid catabolism confers a competitive advantage to pathogenic vibrio cholerae in the mouse intestine.Endothelial adhesion molecule expression and its inhibition by recombinant bactericidal/permeability-increasing protein are influenced by the capsulation and lipooligosaccharide structure of Neisseria meningitidisStructure of the LPS O-chain from Fusobacterium nucleatum strain 10953, containing sialic acid.Lipooligosaccharide and polysaccharide capsule: virulence factors of Neisseria meningitidis that determine meningococcal interaction with human dendritic cells.Acquisition of factor H by a novel surface protein on group B Streptococcus promotes complement degradation.
P2860
Q28474974-BCFB36EC-EE66-4DA5-92B3-259554661412Q30891451-509A95B5-65D2-40A7-B609-5770B3F40D46Q33452919-05073AE0-6FCA-4EDF-95FC-FA7B32B4492FQ33602953-66D5FA83-B7E0-4525-AD59-FF793C770653Q33812435-22F97AA4-0310-41C4-8AFA-058AB1D8D2F0Q33992223-5AD37BAB-83C0-425B-B06B-A4BC0B268495Q34057081-D5585B97-195A-4918-A98F-9D98A1A6125EQ34105747-8C78BDF4-C2C4-4011-9DCB-44091D3B92C6Q34111593-D90F44F8-0BEF-4302-8869-86E89981E7B4Q34126624-6BA009D3-86C4-462B-9E60-0B672D46C23FQ34376170-5E1F2FF9-24E5-4DD3-8047-49562F509FC1Q34601796-468CCABA-CDDF-4F92-8FB1-18712A0AA4B3Q34624357-C0C04D7E-69C2-4703-BAB2-162AD73C387AQ35072338-FCE00A73-EE41-4479-B402-54C6F3CC3B82Q35689526-679E1BDB-9773-4854-8960-EA00E6B12D6EQ35714421-6DCE80C9-79DC-4CD7-A418-242E59D8925DQ36402993-6637A0F4-6987-4B39-9E53-67A02411DA3CQ36422066-5607ECF0-4EE4-42B0-AD75-76831040347FQ36470692-C1B07F8B-107C-435B-BA89-CD94DBDEECDEQ36847072-375EB407-983A-408B-81C4-77261C6F2DEEQ37191341-2554C439-9C22-4C35-907C-ED2FE424BDB8Q37333420-2197861D-2554-4245-882A-B4155DCE7E37Q38319197-51787538-B620-4050-9779-0DF75D3C384FQ38960135-FAC688D0-83D3-4C37-8AF1-9A4672B99D6CQ39654947-AC0B8921-BD6C-4438-891B-9BD8EB7FAE9CQ42626245-C1019CA3-093B-409D-91FC-6578264A373F
P2860
Role of lipopolysaccharide sialylation in serum resistance of serogroup B and C meningococcal disease isolates.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Role of lipopolysaccharide sia ...... eningococcal disease isolates.
@en
Role of lipopolysaccharide sia ...... eningococcal disease isolates.
@nl
type
label
Role of lipopolysaccharide sia ...... eningococcal disease isolates.
@en
Role of lipopolysaccharide sia ...... eningococcal disease isolates.
@nl
prefLabel
Role of lipopolysaccharide sia ...... eningococcal disease isolates.
@en
Role of lipopolysaccharide sia ...... eningococcal disease isolates.
@nl
P2093
P2860
P1476
Role of lipopolysaccharide sia ...... meningococcal disease isolates
@en
P2093
P2860
P304
P407
P577
1999-02-01T00:00:00Z